Literature DB >> 15820302

Tachycardia amongst subjects recovering from severe acute respiratory syndrome (SARS).

Suet-Ting Lau, Wai-Cho Yu, Ngai-Shing Mok, Ping-Tim Tsui, Wing-Lok Tong, Stella W C Cheng.   

Abstract

SARS is a new infection in human. Patients recovering from SARS had palpitation in the form of sinus tachycardia. This study to identify the possible causes for the tachycardia excluded active disease, thyroid dysfunction, haematological, cardiac, autonomic and significant pulmonary defect at 2 months from onset of disease. The symptomatology was attributed to physical deconditioning and anxiety state. Physical and psychological fitness should be restored with rehabilitation.

Entities:  

Mesh:

Year:  2005        PMID: 15820302      PMCID: PMC7132412          DOI: 10.1016/j.ijcard.2004.06.022

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


SARS is a new infection in humans caused by a novel coronavirus [1] with unknown medium- or long-term complications. Hong Kong reported a total of 1755 cases and 299 deaths. Palpitation in the form of tachycardia at rest and becoming more marked during mild exertion was noted amongst patients recovering from SARS. Possible causes are deconditioning [2], impaired pulmonary function, impaired cardiac function, cardiac arrhythmia, thyroid dysfunction, anaemia, autonomic dysfunction [3] and anxiety state. This prospective cross-sectional cohort study was conducted to assess the extent of tachycardia and identify possible cause for it. Fifteen consecutive patients with resting heart rate of more than 90 beats per min (BPM) were recruited from the initial 100 patients who underwent lung function testing at about 2 months from onset of illness. All patients had at least 4-fold rise in SARS-coronavirus antibody titre. The resting 12-lead ECGs showed a sinus heart rate ranging from 90 to 109 BPM. Holter monitoring results are listed in Table 1 . Overall heart rate faster than 100 BPM was observed during the daytime (9am–9pm) but not at night. No other arrhythmia was detected. Heart rate variability using the time domain analysis showed that the standard deviation of all normal RR interval (SDNN) was normal (>100 ms in patients <60 years of age and 97 ms in the 62-year-old patient) (Table 1). Signal-average ECG was within normal in all subjects. Echocardiography revealed no abnormality apart from the 62-year-old patient who had mild diastolic dysfunction.
Table 1

Holter monitoring and pulmonary function test

SexAgeMin HRMax HRMean HRHR variability SDNN (ms, N>100ms)FEV1 % predictedTLC % predictedDLCO/VA % predictedPFT interpretation
1M2550141871339797103Normal
2F304615477181107102127Normal
3F2547153841677178120Restrictive mild
4M4052136821318610192Normal
5F3461152851047890128Restrictive mild
6F285314591123527895Restrictive moderate
7M335013787118798579Restrictive mild
8M495114283137120121128Normal
9F26491297713584114123Normal
10F39511167910310912197Normal
11M625311470979812388Normal
12M36571238311111291110Normal
13F255516385147107102NANormal
14M265414783122798297Restrictive very mild
15M47501358214091103103Normal

Age=Age in years; Min HR=Minimum heart rate beats per minute; Max HR=Maximum heart rate beats per minute; SDNN=Standard deviation mean RR interval; FEV1%=Force expiratory volume in the first second; TLC%=Total lung capacity; DLCO/VA%=Diffusing capacity for carbon monoxide corrected for alveolar volume; PFT=Pulmonary function test.

Holter monitoring and pulmonary function test Age=Age in years; Min HR=Minimum heart rate beats per minute; Max HR=Maximum heart rate beats per minute; SDNN=Standard deviation mean RR interval; FEV1%=Force expiratory volume in the first second; TLC%=Total lung capacity; DLCO/VA%=Diffusing capacity for carbon monoxide corrected for alveolar volume; PFT=Pulmonary function test. Only one patient had a moderate restrictive pulmonary function defect (Table 1). Chest radiography findings, haemoglobin level, length of hospital stay, time elapsed after discharge, presence of complications, WHO Quality of Life (QOL) score and Monitored Functional Task Evaluation (MFTE) score [4] are shown in Table 2 .
Table 2

Other factors

CXR findingHb (g/dl)LOS (days)Discharge to PFT (days)ComplicationQOL
MFTE
Physical health domainPsychological health domain
III
1Mottling RLZ133531AD75636920
2N12.82536AD*44*50*5020
3Bilat shadowing13.35421SP, CI69697519.4
4N14.53714Pne56*44*5019.7
5Bilat lower zone hazziness12.83018ICU75757518.8
6Bilat lower zone hazziness12.93923ICU88818119.5
7Bilat middle zone hazziness14.13521ICU63757518.7
8Mild hazziness RLZ, LMZ13.12151AD69636320
9N13.92433AD63565619.6
10Bilat lower zone hazziness10.63118UTI63566320
11N12.6183463*50*5018.8
12Bilat diffuse hazziness14.62145CI75636319.8
13N13.62121CI55*505617.6
14Bilat M and LZ hazziness14.92523ITP69*505620
15Bilat lower zone hazziness13.52929ICU63*25*3819.2

Hb=Haemoglobin level; LOS=Length of hospital stay; Discharge to PFT=Discharge to day of pulmonary function test in days; ICU=ICU Care; ITP=Idiopathic thrombocytopenic purpura; UTI=Urinary tract infection; CI=Chest infection; CD=Anxiety depression; SP=Steroid psychosis; Pne=Pneumomediastinum and subcutaneous emphysema; QOL=Quality of life score; MFTE=Monitoring functional task evaluation; *=Score<50; QOL score—Normal>75; MFTE score—Normal>20.

Other factors Hb=Haemoglobin level; LOS=Length of hospital stay; Discharge to PFT=Discharge to day of pulmonary function test in days; ICU=ICU Care; ITP=Idiopathic thrombocytopenic purpura; UTI=Urinary tract infection; CI=Chest infection; CD=Anxiety depression; SP=Steroid psychosis; Pne=Pneumomediastinum and subcutaneous emphysema; QOL=Quality of life score; MFTE=Monitoring functional task evaluation; *=Score<50; QOL score—Normal>75; MFTE score—Normal>20. The normal CBP, ESR, LFT, LDH, CK, CRP, as well as results of clinical assessment, suggested that ongoing active disease is unlikely. Normal thyroid function tests excluded thyrotoxicosis. Although coronavirus infection had been demonstrated to cause an autoimmune myocarditis in rabbits that may progress to dilated cardiomyopathy [5], normal troponin I, echocardiography and other negative cardiac investigations in our cohort excluded myocarditis and cardiomyopathy. Mild residual CXR changes, minor lung function impairment and normal blood gas makes pulmonary defect unlikely to be a significant cause of sinus tachycardia during normal activity. This cohort of patients had more severe disease with a high proportion having various complications. The prolonged hospitalization of 18–54 days together with confinement at convalescence could lead to physical deconditioning. The QOL domain score was impaired (score<75) in 11/15 in physical health, 13/15 in psychological well-being, with a very low score of ≤50 in six patients. MFTE score was less than 20 (range 17.6–19.7) in 10 patients indicating the presence of mild functional difficulties. Deconditioning and anxiety state causes tachycardia in the daytime but not at night, and is compatible with the pattern observed in this cohort. In the absence of significant cardiac, pulmonary, thyroid and haematological dysfunction, we believe that sinus tachycardia is attributable to physical deconditioning and contributed by impaired psychological well-being. Appropriate rehabilitation programs should be instituted to enhance recovery of physical and psychological fitness.
  4 in total

1.  Cardiovascular function following reduced aerobic activity.

Authors:  P B Raven; R M Welch-O'Connor; X Shi
Journal:  Med Sci Sports Exerc       Date:  1998-07       Impact factor: 5.411

Review 2.  Regulation of sympathetic nervous system function after cardiovascular deconditioning.

Authors:  E M Hasser; J A Moffitt
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

3.  Rabbit cardiomyopathy associated with a virus antigenically related to human coronavirus strain 229E.

Authors:  J D Small; L Aurelian; R A Squire; J D Strandberg; E C Melby; T B Turner; B Newman
Journal:  Am J Pathol       Date:  1979-06       Impact factor: 4.307

4.  A novel coronavirus associated with severe acute respiratory syndrome.

Authors:  Thomas G Ksiazek; Dean Erdman; Cynthia S Goldsmith; Sherif R Zaki; Teresa Peret; Shannon Emery; Suxiang Tong; Carlo Urbani; James A Comer; Wilina Lim; Pierre E Rollin; Scott F Dowell; Ai-Ee Ling; Charles D Humphrey; Wun-Ju Shieh; Jeannette Guarner; Christopher D Paddock; Paul Rota; Barry Fields; Joseph DeRisi; Jyh-Yuan Yang; Nancy Cox; James M Hughes; James W LeDuc; William J Bellini; Larry J Anderson
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

  4 in total
  18 in total

Review 1.  Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies.

Authors:  Francisco Carmona-Torre; Ane Mínguez-Olaondo; Alba López-Bravo; Beatriz Tijero; Vesselina Grozeva; Michaela Walcker; Harkaitz Azkune-Galparsoro; Adolfo López de Munain; Ana Belen Alcaide; Jorge Quiroga; Jose Luis Del Pozo; Juan Carlos Gómez-Esteban
Journal:  Front Neurol       Date:  2022-05-27       Impact factor: 4.086

Review 2.  Arrhythmia in COVID-19.

Authors:  Savalan Babapoor-Farrokhran; Roozbeh Tarighati Rasekhi; Deanna Gill; Shaghayegh Babapoor; Aman Amanullah
Journal:  SN Compr Clin Med       Date:  2020-08-14

Review 3.  Post-acute COVID-19 syndrome.

Authors:  Ani Nalbandian; Kartik Sehgal; Aakriti Gupta; Mahesh V Madhavan; Claire McGroder; Jacob S Stevens; Joshua R Cook; Anna S Nordvig; Daniel Shalev; Tejasav S Sehrawat; Neha Ahluwalia; Behnood Bikdeli; Donald Dietz; Caroline Der-Nigoghossian; Nadia Liyanage-Don; Gregg F Rosner; Elana J Bernstein; Sumit Mohan; Akinpelumi A Beckley; David S Seres; Toni K Choueiri; Nir Uriel; John C Ausiello; Domenico Accili; Daniel E Freedberg; Matthew Baldwin; Allan Schwartz; Daniel Brodie; Christine Kim Garcia; Mitchell S V Elkind; Jean M Connors; John P Bilezikian; Donald W Landry; Elaine Y Wan
Journal:  Nat Med       Date:  2021-03-22       Impact factor: 53.440

4.  Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic.

Authors:  Jonathan P Rogers; Edward Chesney; Dominic Oliver; Thomas A Pollak; Philip McGuire; Paolo Fusar-Poli; Michael S Zandi; Glyn Lewis; Anthony S David
Journal:  Lancet Psychiatry       Date:  2020-05-18       Impact factor: 27.083

Review 5.  Cardiac and arrhythmic complications in patients with COVID-19.

Authors:  Adriano Nunes Kochi; Ana Paula Tagliari; Giovanni Battista Forleo; Gaetano Michele Fassini; Claudio Tondo
Journal:  J Cardiovasc Electrophysiol       Date:  2020-04-13

Review 6.  Management of Arrhythmias Associated with COVID-19.

Authors:  Amar D Desai; Brian C Boursiquot; Lea Melki; Elaine Y Wan
Journal:  Curr Cardiol Rep       Date:  2020-11-24       Impact factor: 2.931

Review 7.  Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection.

Authors:  Fulton A Robinson; Ryan P Mihealsick; Brant M Wagener; Peter Hanna; Megan D Poston; Igor R Efimov; Kalyanam Shivkumar; Donald B Hoover
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-09       Impact factor: 4.733

8.  Fatigue following COVID-19 infection is not associated with autonomic dysfunction.

Authors:  Liam Townsend; David Moloney; Ciaran Finucane; Kevin McCarthy; Colm Bergin; Ciaran Bannan; Rose-Anne Kenny
Journal:  PLoS One       Date:  2021-02-25       Impact factor: 3.240

Review 9.  The cardiac complications of COVID-19: many publications, multiple uncertainties.

Authors:  Abdallah Al-Mohammad; David G Partridge; Graham Fent; Oliver Watson; Nigel T Lewis; Robert F Storey; Michael Makris; Timothy J Chico
Journal:  Vasc Biol       Date:  2020-10-20

10.  Subacute thyroiditis associated with COVID-19.

Authors:  Shaikh Abdul Matin Mattar; Samuel Ji Quan Koh; Suresh Rama Chandran; Benjamin Pei Zhi Cherng
Journal:  BMJ Case Rep       Date:  2020-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.